Back to top

biotechnology: Archive

Zacks Equity Research

NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity

Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change

Zacks Equity Research

INCY Announces New Late-Stage Data on Skin Disease Drug

Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.

NVSNegative Net Change INCYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change

Ahan Chakraborty

Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.

NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change

Ahan Chakraborty

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change

Zacks Equity Research

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.

ZTSNegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change

Zacks Equity Research

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change RAPPPositive Net Change

Zacks Equity Research

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

AZNPositive Net Change NVSNegative Net Change PFEPositive Net Change OLMANegative Net Change

Ekta Bagri

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change

Ekta Bagri

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change

Zacks Equity Research

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

CRMDNegative Net Change KNSANegative Net Change TVTXPositive Net Change PHARPositive Net Change

Zacks Equity Research

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTANegative Net Change

Ekta Bagri

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change

Zacks Equity Research

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

NVSNegative Net Change NVOPositive Net Change ARWRNegative Net Change TRMLNegative Net Change

Ahan Chakraborty

Is NVO's Major Restructuring Plan an Indication to Sell the Stock?

Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.

NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXNegative Net Change

Ahan Chakraborty

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change

Zacks Equity Research

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.

RARENegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change